Shamburg News · 8-K filed Nov 13, 2026, 8:05 AM EST

PDS Biotechnology Reports Third Quarter 2026 Financial Results and Business Update

PDSB · PDS Biotechnology Corp

  • Earnings
  • Financing
  • Leadership change
  • Other event
  • Materiality: high

PDS Biotechnology Corporation reported a net loss of $7.6 million, or $0.11 per basic and diluted share, for the quarter ended September 30, 2026, compared with $9.0 million, or $0.19 per share, a year earlier. Research and development expenses were $2.1 million and general and administrative expenses were $3.8 million for the quarter. The company reported cash and cash equivalents of $15.2 million as of September 30, 2026, and announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001140361-26-043542.

Written from the filing by Shamburg Markets. Figures are as reported by the company.